IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $49.12 million. The enterprise value is $46.11 million.
Important Dates
The next estimated earnings date is Tuesday, November 25, 2025, before market open.
| Earnings Date | Nov 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 68.95 million shares outstanding. The number of shares has increased by 19.84% in one year.
| Current Share Class | 68.95M |
| Shares Outstanding | 68.95M |
| Shares Change (YoY) | +19.84% |
| Shares Change (QoQ) | +1.79% |
| Owned by Insiders (%) | 40.43% |
| Owned by Institutions (%) | 0.35% |
| Float | 41.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.32 |
| Forward PS | 11.34 |
| PB Ratio | 14.47 |
| P/TBV Ratio | 16.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.82.
| Current Ratio | 1.18 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -230.80% and return on invested capital (ROIC) is -120.95%.
| Return on Equity (ROE) | -230.80% |
| Return on Assets (ROA) | -76.40% |
| Return on Invested Capital (ROIC) | -120.95% |
| Return on Capital Employed (ROCE) | -537.63% |
| Revenue Per Employee | $42,227 |
| Profits Per Employee | -$236,061 |
| Employee Count | 66 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.68% in the last 52 weeks. The beta is 2.25, so IceCure Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.25 |
| 52-Week Price Change | -15.68% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 25.19 |
| Average Volume (20 Days) | 1,453,336 |
Short Selling Information
The latest short interest is 1.55 million, so 2.25% of the outstanding shares have been sold short.
| Short Interest | 1.55M |
| Short Previous Month | 591,931 |
| Short % of Shares Out | 2.25% |
| Short % of Float | 3.78% |
| Short Ratio (days to cover) | 0.64 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $2.79 million and -$15.58 million in losses. Loss per share was -$0.28.
| Revenue | 2.79M |
| Gross Profit | 1.00M |
| Operating Income | -15.86M |
| Pretax Income | -15.58M |
| Net Income | -15.58M |
| EBITDA | -15.54M |
| EBIT | -15.86M |
| Loss Per Share | -$0.28 |
Full Income StatementBalance Sheet
The company has $5.38 million in cash and $2.37 million in debt, giving a net cash position of $3.01 million or $0.04 per share.
| Cash & Cash Equivalents | 5.38M |
| Total Debt | 2.37M |
| Net Cash | 3.01M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 2.89M |
| Book Value Per Share | 0.05 |
| Working Capital | 1.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.20 million and capital expenditures -$65,000, giving a free cash flow of -$14.26 million.
| Operating Cash Flow | -14.20M |
| Capital Expenditures | -65,000 |
| Free Cash Flow | -14.26M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
| Gross Margin | 35.92% |
| Operating Margin | -569.07% |
| Pretax Margin | -559.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.84% |
| Shareholder Yield | -19.84% |
| Earnings Yield | -31.72% |
| FCF Yield | -29.03% |
Analyst Forecast
The average price target for IceCure Medical is $2.50, which is 250.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.50 |
| Price Target Difference | 250.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 93.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IceCure Medical has an Altman Z-Score of -15.36 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.36 |
| Piotroski F-Score | 2 |
